Ascent Capital Management LLC Makes New Investment in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Ascent Capital Management LLC bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 4,935 shares of the exchange traded fund’s stock, valued at approximately $444,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in SPDR S&P Biotech ETF by 198.6% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock worth $911,825,000 after acquiring an additional 6,138,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of SPDR S&P Biotech ETF in the 3rd quarter worth approximately $141,284,000. Proficio Capital Partners LLC increased its holdings in SPDR S&P Biotech ETF by 16,156.1% during the fourth quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock valued at $82,615,000 after buying an additional 911,686 shares during the period. Mirae Asset Securities USA Inc. increased its holdings in SPDR S&P Biotech ETF by 50.0% during the third quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after buying an additional 300,000 shares during the period. Finally, Raymond James Financial Inc. bought a new position in SPDR S&P Biotech ETF in the fourth quarter worth approximately $55,529,000.

SPDR S&P Biotech ETF Trading Up 1.3 %

Shares of NYSEARCA XBI opened at $87.13 on Friday. SPDR S&P Biotech ETF has a 12-month low of $81.14 and a 12-month high of $105.47. The stock’s fifty day simple moving average is $90.06 and its two-hundred day simple moving average is $94.82. The stock has a market capitalization of $5.65 billion, a PE ratio of 11.47 and a beta of 0.99.

About SPDR S&P Biotech ETF

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Stories

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.